Jun 22, 2011 · One frequently reads that an adverse effect may occur if a certain drug is given to someone who is already taking cyp3a inhibitors or inducers. Answer this question The …

Feb 3, 2025 · Avoid using this medicine with strong or moderate CYP3A inducers. CYP3A substrates: If Journavx is used together with sensitive CYP3A substrates or CYP3A substrates …

Nov 25, 2024 · While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong …

Jul 10, 2024 · Concomitant use with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations, increasing risk of drug-related toxicity. If concomitant use of the strong …

Mar 12, 2024 · Use of CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients taking CYP2D6 or CYP3A inhibitors, depending on CYP2D6 …

Feb 6, 2025 · Adverse Reactions with Concomitant Use with CYP3A Inhibitors: Concomitant use with strong or moderate CYP3A inhibitors increased vanzacaftor, tezacaftor, and deutivacaftor …

Mar 10, 2025 · Cautions for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Contraindications. Concomitant use with drugs highly dependent on CYP3A for metabolism …

Feb 24, 2025 · Strong CYP3A Inducers. An increase in dosage of REMERON/REMERONSolTab may be needed with concomitant strong CYP3A inducer (e.g., carbamazepine, phenytoin, …

Nov 21, 2023 · Strong CYP3A Inhibitors: If possible, avoid taking strong CYP3A Inhibitors with this medicine; if you can not avoid using both medicines together, then reduce Truqap dose. …

May 2, 2024 · moderate CYP3A inducers: bosentan, cenobamate, dabrafenib, efavirenz, etravirine, lorlatinib, pexidartinib, phenobarbital, primidone, sotorasib Pirtobrutinib may also …